NCT00508742

Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization

A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization With Vaccine Serotypes of Streptococcus Pneumoniae in Healthy Infants in Israel.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,866 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 42 Days – 98 Days
• Healthy volunteers: Accepted

Summary

This study is designed to assess the impact of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) on nasopharyngeal colonization with Streptococcus pneumoniae in healthy infants.

Conditions

• Pneumococcal Infections

Interventions

Type	Name	Description
BIOLOGICAL	13-valent Pneumococcal Conjugate Vaccine	1 dose at 2, 4, 6 and 12 months of age
BIOLOGICAL	7 valent pneumococcal conjugate vaccine	1 dose at 2, 4, 6 and 12 months of age

Timeline

• Start date: 2007-12-01
• Primary completion: 2011-08-01
• Completion: 2011-08-01
• First posted: 2007-07-30
• Last updated: 2013-05-10
• Results posted: 2012-07-13

Locations

5 sites across 1 country: Israel